CD274 and metastatic malignant neoplasm: Anti‐PD‐1 and anti‐PD‐L1 antibodies as checkpoint blockade immunotherapies combined with RT were shown to extensively advance the coordinated response ratios in different essential and metastatic cancer therapeutics.163 Similarly, current examinations anticipate that binary pathways, i.e., mutational loads of IFN‐γ pathways and DNA damage signaling pathways, are associated with immune regulation of PD‐L1 induction in tumors.